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Law an Independent Variable: Firms’ Response to Affordable Care Act 
Christopher M. Bays, 
Health Data & Analysis 
April 26, 2013 
  
I. Intro 
In 2010, Congress passed the Patient Protection and Affordable Care Act (PPACA) 
which created an individual mandate for every American to carry health insurance or face 
financial penalties. The end result is the single largest increase in the number of insured 
Americans since the creation of Medicare under Lyndon B Johnson’s Great Society 
Program.
1
 The drafters of PPACA emphasized three main objectives: 1) to provide access 
to healthcare to all; 2) to improve quality of care; and 3) to find ways to slow or reduce the 
cost of care. 
2
 In expanding healthcare coverage to more than 30 million Americans 
currently without insurance, the act will guarantee that many who need medical care will 
not be left hanging.
3
 
However, after the Supreme Court’s recent ruling upholding the key components of 
PPACA the mere validation of the healthcare bill has hardly ended the debate. Healthcare 
organizations face a unique and wide-ranging set of challenges as a result of this 
                                                          
1
 Ben Shepherd, A new Focus: How to Profit from Healthcare Reform, Investing Daily (January 14, 2013), available 
at http://www.investingdaily.com/16082/a-new-focus-how-to-profit-from-healthcare-reform 
2
 Ron Rimkus, The economics of Obamacare: The implications for Healthcare Investing, Enterprising Investor (July 
11, 2012), available at  http://blogs.cfainstitute.org/investor/2012/07/11/the-economics-of-obamacare-the-
implications-for-healthcare-investing/ 
3
 The Lurking Danger in the Affordable Care Act, Daily Finance (October 2, 2012), available at 
www.dailyfinance.com/2012/10/02/the-lurking-danger-in-the-affordable-care-act/ 
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legislation, from payment to reimbursement reform.
4
  These changes, regardless of whether 
critics are in favor or against the reform, will have a drastic effect outside the healthcare 
market.  PPACA will affect employment practices, tax considerations and the way 
individuals and firms invest their money.
5
 One of the controversial provisions in the 
healthcare reform bill, which will have these cross market effects, is the new tax on 
medical device sales.  This new 2.3% tax on the United States sale of medical devices 
began in January 2013.
6
  This tax will be assessed on revenues of the devices not solely 
profits.
7
  On top of federal, state and local taxes companies in 2013 are anticipating to pay 
approximately 50 percent of every dollar earned.
8
 
With the healthcare industry becoming an integral part of the United States 
economy; it will be critical for investors to maintain exposure to the changes they face with 
the implementation of PPACA in order for them to enjoy robust gains, sustain a solid 
footing in the healthcare industry and maintain a diversified portfolio.  This paper will 
focus on the public policy implication of policy makers need to be conscious  of market 
trends and Wall Street perceptions when determining the full effect of their legislation. Part 
2 of the paper will discuss the projected effects of the implementation on PPACA on the 
healthcare industry.  Specifically, this paper will focus on how investors, brokers and 
investment firms will be affected by the new Medical Loss Ratios (MLR) regulations on 
                                                          
4
 Affordable Care Act Update: Implementing Medicare Cost Saving, CMS Office of the Actuary (June 8, 2010), 
available at http://www.cms.gov/apps/docs/aca-update-implementing-medicare-costs-savings.pdf 
5
 Jim Blankenship, What Obamacare Will Do to Your Taxes, Forbes (July 9, 2012), available at 
http://www.forbes.com/sites/advisor/2012/07/09/what-obamacare-will-do-to-your-taxes/ 
6
 Just the Facts: The Medical Device Excise Tax, MedReps.com(Last Visited February, 27 2013), available at 
http://www.medreps.com/medical-sales-careers/medical-device-excise-tax/  
7
 Ruth Hoffman, KPMG TaxWatch Recap: New Medical Device Excise Tax, KPMG (2012), available at 
http://www.us.kpmg.com/microsite/taxnewsflash/2012/Jan/Excise.v5_web.pdf. The tax is levied against medical 
device manufacturer’s revenues regardless of whether the manufacturer has a profit. 
8
  Devon Herrick, The Job-Killing Medical Device Tax, National Center for Policy Analysis (February 2012), Issue 
Brief No. 106,  http://www.ncpa.org/pdfs/ib106.pdf  
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issuers, formation of Accountable Care Organizations (ACOs) and the new tax on medical 
devices.  These new implications will have a direct effect on their corresponding markets, 
for instance; Formation of ACOs will affect the way hospitals operate, medical device 
manufacturers will have to adapt to the way medical devices are developed and sold and 
MLR regulations will impact how issuers price their products and the quality of service.  
However, with the passage of the Affordable Care Act (“ACA”) still in its infancy the full 
effect of these provisions are only mere speculations. 
This uncertainty has led analysts looking to invest in the healthcare industry to 
project how hospitals, doctors and medical manufactures will react to these new ACA 
regulations.  One particular area of interest is venture capitalist contributions and medical 
technology Initial Public Offerings.  Initial indications express decreasing confidence in 
the upcoming years in these areas and project less funding of research and development as 
well as advancement of startup companies. 
9
 Considering the projections from several 
conflicting analysts as to their anticipated effects on the overall market response to this 
legislation, these opinions will assist us in understanding how investors gain or lose 
confidence in an investment opportunity based on how other perceive the rate of return and 
market stability. While one sub-sector of the healthcare industry see continuous growth and 
revenue, others might discover increased costs due to the need to conform to the new ACA 
standards coupled with a decreased influx of available capital contributions.  
                                                          
9
 Scott Gottlieb, Healthcare consolidation and Competition after PPACA, American Enterprise Institute (May 18, 
2012), http://www.aei.org/speech/health/healthcare-reform/ppaca/health-care-consolidation-and-competition-after-
ppaca/ ;  see also  Allison Bell, Hearing Witness: PPACA Is Scaring Capital Away from Health Services, Life 
Health Pro (May 18, 2012)  http://www.lifehealthpro.com/2012/05/18/hearing-witness-ppaca-is-scaring-capital-
away-from  (discussing the differing views of Scott Gottlieb and Thomas Greaney regarding incentives to invest 
capital) 
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Part 3 of this article will provide a brief overview on how analysts and investors 
determine and assess investment potential value through quantitative analysis. Quantitative 
analysis is a financial analysis technique that seeks to understand behavior by using 
complex mathematical and statistical modeling, measurement and research.
10
 These types 
of financial breakdowns can be done for a number of reasons such as measurement, 
performance evaluation or valuation of a financial instrument.
11
 It can also be used to 
predict real world events such as changes in a share price or to ascertain investment 
quality.
12
 In general, during economic downturns investors need to track pricing and 
premium levels, medical costs and member growth over time, as well as the regulato ry 
noise related to covered charges through the government health programs. Part 3 will 
further discuss how analysts apply quantitative analysis to assess the value of healthcare 
industry investment opportunities. Predominantly, this area will focus on projection 
analysis and financial ratios investors rely on such as Medical Cost Ratio.
13
  In addition, 
investors utilize market data such as the S&P Healthcare Sector Index and return on 
investment breakdowns. Although quantitative analysis is a powerful tool for evaluating 
investments, it rarely tells a complete story without complementary qualitative analysis.  
This article will also discuss other statistics used by investors to obtain an optimal portfolio  
within the healthcare context. 
Part 4 of this article discuss the detachment of policy makers within the health care 
industry who do not appreciate the fragility and instability of capital markets as a result of 
                                                          
10
  Campbell R. Harvey, Quantitative Analysis, Hyper textual Financial Glossary, available at 
http://people.duke.edu/~charvey/Classes/wpg/bfglosq.htm 
11
 Understanding Financial Statements, Dun & Bradstreet (Last Visited April 10, 2013), available at 
http://www.dnb.com/customer-service/understanding-financial-statements.html  
12
 Id. 
13
 Robert Kohut, UnitedHealth Investors: Buy, Sell or Hold?, Wall St. Cheat Sheet (October 27, 2012), available at 
http://wallstcheatsheet.com/stocks/unitedhealth-investors-buy-sell-or-hold.html/  
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the policies they legislate. Using the information gathered by quantitative analytics many 
investors and analysts project trends of investing in the healthcare sector based on this 
information.
14
  In a theory developed by John Maynard Keynes to explain price fluctuations 
in markets, Keynes believed “investors are not looking only at fundamental values, but 
rather on what they think everyone else thinks their value is, or what everybody else would 
predict the average assessment of value to be.”15 Despite some reports focused on the 
opportunity growth and potential investment return for the healthcare industry, others see a 
shrinking market for investment in companies within the early stages of development, in 
particular the medical device sector.  Ultimately, as the market responses to the changes in 
the healthcare sector the medical device tax may only hurt patient care and exacerbate 
current trends of reduced utilization of medical devices.  We may learn that the effect of 
the Affordable Care Act not only affects the regulatory facet of health care but also the 
economic landscape of health care. Artificially capping profits in the health sector may 
mean that venture capitalists and investment firms will find themselves in a position where 
it is no longer profitable to add healthcare companies to their portfolios.
16
  This could 
result in an exodus of capital funding, jobs, and new innovation. 
 
 
                                                          
14
 Suzanne McGee,  Obamacare Ruling: Tricky Investing Terrain, MSN Money (June 29, 2012), available at 
http://money.msn.com/top-stocks/post.aspx?post=2d91f7e6-4ff1-4327-ac83-f27b0fdb317f  
15
 Robert J. Shiller, The Beauty Contest That’s Shaking Wall St., The New York Times (September 3, 2011), 
available at http://www.nytimes.com/2011/09/04/business/economy/on-wall-st-a-keynesian-beauty-
contest.html?_r=0  
16
  Frank Pasquale, Joining or Changing The Conversation: Catholic Social Thought and Intellectual Property, 
Cardozo Arts & Entertainment, Vol. 29:681 p. 687. “Other unintended consequences could emerge. Compulsory  
licensing of essential drugs could lead to a diversion of more  resources to research on nonessential drugs. No one is 
pushing for compulsory licensing for baldness cures or pet medications. In 2008, the purchasing power of the 
average American dog was higher than that of forty percent of the world’s population” 
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II. Implementation of the Affordable Care Act 
a. ACO’s 
ACOs are collaborations that integrate groups of providers formed from a variety of 
entities. These include physicians (particularly primary care physicians), individual 
physicians, hospitals, partnerships and others forms of joint-ventures.
17
  These providers 
work to manage and coordinate care for Medicare and commercial beneficiaries.  A 
common feature of successful ACOs will be its ability to connect and synchronize the 
interests of the providers, payers and patients.
18
 In doing so, these ACOs may receive 
shared-saving bonuses from a payer by achieving measured quality targets and 
demonstrating real reductions in overall spending growth for a defined population of 
patients
19
   
The majority of ACO proposals assume that providers within each community will 
come together to form these integrated delivery models and solicit other providers in the 
community to voluntarily join the ACO.
20
  ACOs aim to change both the philosophy and 
practice patterns of providers and in turn benefit all patients from the delivery of higher-
                                                          
17
 Timony K. Lake, Kate A. Stewart and Paul B. Ginsburg, Lessons from the Field: Making ACOs Real, National 
Institute for Health Care Reform, No.2 (Jan. 2011) 
18
 Elizabeth G. Litten. “ACOs: Getting More for Less?” New Jersey Law Journal Vol. 204- No. 8 (May 23, 2011)  
available at http://www.foxrothschild.com/newspubs/newspubsArticle.aspx?id=4294967686 (last visited April 29, 
2012) 
19
 David Newman, “Accountable Care Organizations and the Medicare Shared Savings Program” Congressional 
Research Service (November 4, 2010), pp. 1. (Quoting Aaron McKethan, Mark McClellan, Elliott Fisher, et al., 
Moving from Volume-Driven Medicine Toward Accountable Care, Health Affairs, Health Affairs Blog, August 20, 
2009. http://www.healthaffairs.org/blog.) available at http://assets.opencrs.com/rpts/R41474_20101104.pdf .  
20
 Centers for Medicare & Medicaid Services: Accountable Care Organizations (Last modified 04/05/2012)  
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ACO/index.html?redirect=/ACO/  (The ACO 
concept envisions multiple providers assuming joint accountability for improving health care quality and slowing 
the growth of health care costs. The concept was also included in national health care reform legislation as one of 
several demonstration programs to be administered by Medicare (Patient Protection and Affordable Care Act, 2010). 
However, ACOs described in health reform legislation are operationally different from other ACO models. The role 
of ACOs in integrating and aligning provider incentives in care delivery requires participating organizations to 
possess certain key competencies.) 
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quality, lower-cost, and better integrated services.
21
 Philosophically, the attention of the 
health care system changes under ACOs from the traditional focus on treating patients with 
truly urgent problems to preventing those conditions in the first place. On the financial 
side, ACOs shift away from paying based on the quantity of services rendered and more 
toward paying based on the quality of services.
22
  Although ACOs may contract with any 
payer (Medicare, Medicaid, or private insurer) to provide services and share in any 
resulting savings, the results from this shift are assumed to be far reaching and favorable 
for the health care delivery system. 
As payment for medical services shifts from fee-for-service to more integrated, 
bundled charges, health providers will have to work together to provide services in a cost -
effective manner. For instance, as physicians begin partnering with hospitals and health 
providers, hospitals face a very unique challenge of establishing a cost-effective ACO, 
conforming to the Medicare Shared Shaving Program criteria, while not losing money.
23
  
Although big integrated hospital systems and academic medical centers are in the best 
position to benefit from the ACO, speculation suggests short term struggles for hospitals 
are to be expected. Hospitals will face the difficult task of learning how to cut costs 
without losing money which will take time.
24
  Additionally, asset management firms like 
                                                          
21
 Stephen G. Pelletier, ACOs: Controlling Costs While Improving Care, Association of American Medical Colleges 
Reporter (February 2011), available at 
https://www.aamc.org/newsroom/reporter/feb11/174756/controlling_costs_while_improving_care.html  
22
 Julie Barnes, The Many Legal Barriers Standing in the way  of Health Care Reform, The Atlantic (March 15, 
2012, 9:02 AM ET), reprinted in Bipartisan Policy  (Posted March 16, 2012), available at 
http://www.theatlantic.com/health/archive/2012/03/the-many-legal-barriers-standing-in-the-way-of-health-care-
reform/254259/ 
23
  Anna Wilde Mathews, Can Accountable-Care Organizations Improve Health Care While Reducing Costs?, Wall 
Street Journal (January 23, 2012), available at 
http://online.wsj.com/article/SB10001424052970204720204577128901714576054.html 
24
 Jenny Gold, FAQ on ACOs: Accountable Care Organizations Explained, Kaiser Health News (October 21, 2011), 
available at http://www.kaiserhealthnews.org/Stories/2011/January/13/ACO-accountable-care-organization-
FAQ.aspx 
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Lazard Asset Management LLC see “managed care, hospitals and post-acute care providers 
as the subsectors most impacted by healthcare reform.  Key factors we consider for 
companies in these subsectors include health insurance coverage changes, profitability 
outlook and potential business model changes as a result of the ACO pilot projects.”25 
ACOs are projected to have a profound impact on other subsectors of the healthcare 
industry as well such as pharmaceutical manufacturing.
26
  One gap in PPACA was the 
inability to create a system for ACOs to limit the patient’s access to cost effective 
treatments.  Essentially, a provider can create internal rules limiting access to the most cost 
effective care, in turn choosing the cheaper of two comparable drugs.
27
 In a study by 
BioTech Stock Research of United Healthcare’s episodic payment system,  
 “providers will be more sensitive to cost. If you have two drugs with 
similar patient outcomes, the least expensive one will be used ﬁrst. As 
we wrote in detail in the April issue of Biotech Monthly, this means 
the one used second will still see revenues but lower revenues due to 
Label Shift
28
 and the Leaky Bucket
29.”30  
                                                          
25
 Ross Seidon, U.S. Healthcare Reform: Drivers, Economics and the Supreme Court, Lazard Asset Management 
LLC (March 2012), available at  http://www.lazardnet.com/confcalls/pdfs/2012/U.S.HealthcareReform-
DriversEconomics_LazardInsights_201203.pdf  
26
 Paul H. Keckley, Ph.D, Value-based Purchasing: A Strategic Overview for Healthcare Industry Stakeholders, 
Deloitte center for Health Solutions (2011), available at  http://www.deloitte.com/assets/Dcom-
UnitedStates/Local%20Assets/Documents/Health%20Reform%20Issues%20Briefs/US_CHS_ValueBasedPurchasin
g_031811.pdf  
27
  Investment Implications of ACOs & IPAB, Biotech Stock Research Monthly Vol. 11, No. 6 (June 2011), available 
at http://www.biotechstockresearch.com/free/v11-n06_IPAB-ACO.pdf  
28
 “Label Shifting” is the process by which a provider alters the drugs they customary prescribe to a similar less 
expensive drug based on external factors 
29
 Yale economist Arthur Okun famously described the "Leaky Bucket" problem as one in which the mechanisms 
necessary to move income from one group to another would inevitably result in losses from, among other things, 
administrative costs of government transfer programs. Intuitive picture of a leaking bucket captured the idea that: 
government policy and "the market" are opposing forces, with the market poised to do its work if only the 
government would get out of the way. 
30
 Paul H. Keckley, supra note 27  
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Under widespread adoption of ACOs, investors are going to have to pay more 
attention to pharmaceutical economic analysis and comparative efﬁcacy data.31 This type of 
change makes companies more price-sensitive when pricing their drugs. Researchers 
suggest it will take longer for ACOs to adopt new drugs than it currently does because of 
questions of cost effectiveness.  However, ACOs will not have a drastic effect on the way 
the market participants invest in healthcare because they offer too little incentive for 
doctors and hospitals to change behavior. With only modest rewards for creating ACOs that 
comply with the Shared-Saving Requirements this will not eliminate and may potentially 
increase rewards to providers from maintaining current costly practices.
32
 While shared 
savings may entice some providers into new arrangements, it provides a relatively weak 
impetus to real change.
33
 With very small incentives, the change will be extremely slow. 
 
b. Medical Device Tax 
When Congress carefully drafted the Affordable Care Act it did so with the intent o f 
not adding to the federal budget deficit.
34
  To help pay for the expansion of health coverage 
to 27 million uninsured Americans, the ACA either reduces Medicare payments or 
increases taxes for a wide range of industries that will benefit from health reform 
                                                          
31
 Nikolas H. Goldberg; Sebastian Schneeweiss, MD, ScD; Mary K. Kowal, BA; Joshua J. Gagne, PharmD, MS 
Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States, JAMA. 
2011;305(17):1786-1789, available at  http://jama.jamanetwork.com/article.aspx?articleid=899516  “Efficacy 
studies are randomized, controlled trials comparing an intervention to a control (often a placebo or a sham 
treatment) on a carefully selected group of subjects under controlled conditions. These studies utilizes a variety of 
data sources, including systematic reviews of existing literature and analysis of secondary data, such as claims data, 
patient registries, and electronic health records.” 
32
 Anna Wilde Mathews, supra note 23 
33
 Judy Feder and David Cutler, Achieving Accountable Care and Affordable Care: Key Health Policy Choices to 
Move the Health Care System Forward, Center for American Progress (December 2010), available at 
http://www.americanprogress.org/wp-content/uploads/issues/2010/12/pdf/affordablecare.pdf 
34
  Paul N. Van de Water, Excise Tax on Medical Devices Should Not BE Repealed: Industry Lobbyists Distorts 
Tax’s Impact, Center on Budget and Policy Priorities (March 11, 2013), available at  http://www.cbpp.org/files/2-
14-12health.pdf  
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including; hospitals, home health agencies, clinical laboratories, health insurance 
providers, drug companies, and manufacturers of medical devices.
35
 
The ACA imposes a tax equal to 2.3% on the sales price of any taxable medical 
device by a medical device manufacturer, producer or importer of such device.
36
 According 
to the Congressional Budget Office (CBO) anticipates that this medical excise tax will 
generate $20 billion dollars.
37
 The excise tax applies to sales after December 31, 2012.
38
 As 
such, medical device manufacturers will need to begin accounting for this tax for all sales, 
other than tax free sales, beginning January 1, 2013
39
 and will need to consider the impact 
of this tax on their 2013 results.
40
 Medical devices encompass an extremely wide range of 
products such as; surgical gloves, dental instruments, wheelchairs, coronary stents, 
artificial knees and hips, defibrillators, cardiac pacemakers, irradiation equipment, and 
advanced imaging technology.  However, the tax does not apply to eyeglasses, contact 
lenses, hearing aids, or any other medical device that the public generally buys at retail for 
individual use.
41
  
                                                          
35
 Peter n. Van de Water, supra note 34 
36
 Affordable Care Act Tax Provisions, Internal Revenue Service (Last Updated March 19, 2013) available at 
http://www.irs.gov/uac/Affordable-Care-Act-Tax-Provisions  
37
 See Congressional Budget Office, Estimates for the Insurance Coverage Provisions of the Affordable Care Act 
Updated for the Recent Supreme Court Decision (July 2012). The ACA comprises the Patient Protection and 
Affordable Care Act (Public Law 111-148) and the provisions of the Health Care and Education Reconciliation Act 
of 2010 (P.L. 111-152) that are related to health care.  
38
 Id. 
39
 Keenan Steiner, Backed By Hatch, Klobuchar, Medical Device Makers Score Victory, Sunlight Foundation 
Reporting Group (April 15, 2013),available at  http://reporting.sunlightfoundation.com/2013/backed-by-hatch-
klobuchar-medical-device-makers-score-victory/ (Currently there is a bipartisian effort to repeal the medical device 
tax. "Momentum is clearly growing in Congress to repeal the medical device tax as Senators continue to hear from 
their constituents that the impact is real.) 
40
 Price Waterhouse Cooper, Medical Device Excise Tax, Pharmaceutical and Life Sciences Industry Alert (2012-
13), available at http://www.pwc.com/en_US/us/cfodirect/assets/pdf/insight/pls-alert-2012-3-medical-device-excise-
tax-final.pdf  
41
 The excise tax is established by section 1405 of the Health Care and Education Reconciliation Act of 2010 (Public 
Law 111-152), which effectively substituted for section 9009 of the Patient Protection and Affordable Care Act of 
2010 (Public Law 111-148). 
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In 2011 the Advanced Medical Technology Association (AdvaMed) and Furchtgott-
Roth Economic Enterprises conducted a study which found that:  
"The effect of the tax on earnings of U.S. companies is likely to be 
significant.  In 2006, medical device manufacturers reported taxable 
income of $13.7 billion and paid $3.1 billion in corporate taxes.   The 
new 2.3 percent excise tax will roughly double their total tax bill and 
raise the average effective corporate tax rate to one of the highest 
effective tax rates faced by any industry in the world."
42
  
The U.S. medical device industry has estimated total sales of $106 billion to $116 billion a 
year.
43
 For example, Johnson and Johnson’s worldwide sales of medical devices and 
diagnostics totaled $27 billion in 2012.
44
  The firm had total sales (on both medical devices 
and other products) of $67 billion on which it earned profits of nearly $11 billion.
45
 The 
effect of the tax on earnings of U.S. companies is likely to reduce their net profits from a 
low of 6.8 percent to a high of 40 percent.
46
 
Although venture capitalist and investors have mixed views on the effectiveness of 
the ACA, it seems to be unanimous when it comes to medical devices tax that skepticism is 
high and confidence is at an all-time low. In a LinkedIn poll taken from over 550 members 
of the Medical Device Group, Medcity News found “35  percent of respondents said they 
expected 2013 to be a bad year for the medical device industry, citing problems with 
higher-priced devices that provide minimal advantages among areas of concern and lack of 
                                                          
42
 Diana Furchtgott-Roth and Harold Furchtgott-Roth, Employment Effects of the New Excise Tax on The Medical 
Device Industry (September 2011), available at 
http://www.chi.org/uploadedFiles/Industry_at_a_glance/090711EmploymentEffectofTaxonMedicalDeviceIndustryF
INAL.pdf 
43
 Christopher Flavelle, Medical Device Industry Overstates Tax Impact, Bloomberg Government Study, February 9, 
2012. 
44
 Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results, January 22, 2013, available at 
http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=734718 
45
Id. 
46
 Diana Furchtgott-Roth and Harold Furchtgott-Roth, supra note 42 
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investments.”47 Exacerbating the lack of confidence, a PricewaterhouseCoopers MoneyTree 
Report found that medical device companies received a combined $434 million from 65 
deals in the third quarter, which marks a 37 percent drop in dollar amount and a 27 percent 
decline in the number of deals from the second quarter.
48
 Furthermore, Med Tech Initial 
Public Offerings (IPOs) have been virtually non-existent in the past four years which 
serves as another indicator of a change in the industry’s health.   Additionally, 
PricewaterhouseCoopers also found that Venture Capital Deals were cut in half from 2010 
to 2011 from 54 to 22 respectively.
49
   Given the amount of innovation of medical devices 
that come from smaller companies, that require such capital investments from large players 
in the industry or venture capitalist firm, Bill Trainor of Mutual Capital Partners Fund is 
confident investors will have to change the way the manage their portfolios.
50
  Other 
sources, such as Terry McGuire, co-founder of Polaris Venture Partners, explained “the 
excise tax is clearly a burden, but hardly a driving factor in investment decisions.”51  
Although there seems to be some optimism for the medical device industry, now is not an 
advantageous time to implement such an excise tax. Since the medical industry has been 
struggling for the past three years such an excise tax would hinder the flow of capital 
investments to medical device manufactures.
52
   A study of Universal HealthCare in 
Massachusetts provides an example of what might happen nationwide.  The reports showed 
                                                          
47
 Deanna Pogorelc, The Best and Worst Bets for Healthcare Investing in 2013, MedCity News (December 21, 
2012), available at http://medcitynews.com/2012/12/the-best-worst-bets-for-healthcare-investing-in-2013/  
48
 Venture Capital Investments Decline in Dollars and Deal Volume in Q3 2012, Pricewaterhouse Cooper LLP 
(October 19, 2012), http://www.pwc.com/us/en/press-releases/2012/venture-capital-investments-q3-2012-press-
release.jhtml   
49
 Matt Dolan, Innovation 101—Technology & Innovation in the Medical Device Industry, Roth Capital Partners 
LLC (September 13, 2012), available at 
http://www.roth.com/files/marketing/email_blasts/Roth%20Capital%20CONNECT.pdf 
50
 Pogoreic, supra note 47 
51
 Dan Primack, Is Obamacare Killing Medical Device Startups?, CNN Money (December 6, 2012), 
http://finance.fortune.cnn.com/2012/12/06/is-obamacare-killing-medical-device-startups/  
52
 Matt Dolan, supra note 49 
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that in Massachusetts, 8 out of 9 companies experienced negative comparative growth rates 
in Massachusetts as compared to the rest of the US following the implementation of 
universal health care in that state.
53
    Despite the assumption that medical device 
manufacturers would benefit from the windfall of formerly uninsured customers now 
insured under ACA, there is little data to suggest that such a conclusion after comparing 
the average age of a medical device patient (60 years of age) to new insured customers (45 
years of age).
54
 Using six case studies, Roth Capital Investments found that trends in 
Massachusetts, contrary to an expectation for higher medical device utilization rates, 
actually lagged the rest of the US in the years following the legislation of universal health 
care. 
55
    
c. Medical Loss Ratio 
Another regulation enacted as part of the Affordable Care Act was the imposition of 
reporting and rebating requirements upon insurers in order to promote efficiency.  
Beginning in August 2012, insurers must report plan costs for the purpose of calculating 
their medical loss ratio (the percentage of insurance premium dollars spent on 
reimbursement for clinical services and activities to improve healthcare quality).
56
 Large 
group insurers must spend at least 85 percent of premium dollars on claims and activities to 
improve healthcare quality.
57
 Individual and small group insurers (those with a total 
                                                          
53
 Thomas Sullivan, Affordable Care Act: Medical Device Tax a Problem for Innovation, Policy and Medicine 
(November 5, 2012), available at http://www.policymed.com/2012/11/affordable-care-act-medical-device-tax-a-
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54
 Matt Dolan, supra note 52 
55
 Thomas Sullivan, supra note 53 
56
 Gensina Seiler, Look Out, Look Out: Here Comes Obamacare, 22 No. 1 Wis. Emp. L. Letter 1 
57
 U.S. Department of Health and Human Services, New Afforbale Care Act rules give consumers better value for 
insurance premium, HHS (November 22, 2010), available at 
http://www.hhs.gov/news/press/2010pres/11/20101122a.html; see also Medical Loss Ratio: Getting Your Money’s 
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average of one to 50 employees based on the preceding calendar year, depending on the 
state's definition) must spend at least 80 percent of premium dollars on claims and 
activities to improve healthcare quality.
58
 This efficiency is measured through the “Medical 
Loss Ratio” (MLR), which according to the Act, tracks the percentage of premium dollars 
actually expended on health care services or on efforts to improve the quality of health care 
services.
59
  The ACA requires each insurer to report, on an annual basis, the percentage of 
its annual premium receipts that have been applied to medical services or improvements to 
medical services.
60
  In essence, the medical loss ratio is intended to limit the amount of 
overhead that an insurer can carry (and, by implication, profit levels and executive 
compensation) by requiring the insurer to rebate to its policyholders and plan participants 
any premium revenue in excess of the overhead amount allowed by the Act. 
61
 
Professor Tara Ragone
62
 defines the MLR as a calculation where “the numerator of 
the ratio containing the insurance company’s expenses related to health care, and the 
denominator contains the premiums collected by the insurance company.
63
 Which expenses 
may be included in the numerator and what adjustments insurers may or must make to the 
denominator greatly affect the resulting MLR. Prior to the ACA, some states but not the 
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LLP (November 15, 2012), available at http://www.martindale.com/insurance-law/article_Thorp-Reed-Armstrong-
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Federal government regulated loss ratios.”64 If an insurance company's MLR falls below 
the 80% or 85% threshold, the company must send rebates to the people it insures .
65
 Not 
every state required insurance companies to calculate their MLR, and those that did used 
various definitions and formulae for calculating this ratio.
66
  However, the new “Medical 
Loss Ratio” system is entirely novel in a number of respects: 1) unlike loss ratio regulation 
under existing state statutes, the “Medical Loss Ratio” treats administrative expenses 
relating to healthcare quality improvement differently from other administrative expenses, 
2) rates are reviewed retroactively rather than the prospective review that is the norm under 
state rate regulation statutes, 3) the medical loss ratio refunds apply to large group 
coverage, which has not generally been subject to rate regulation in the past, and 4) the 
medical loss ratio refunds will be computed by broad categories
67
 rather than on a product-
specific basis.
68
 This Federal mandate has led to heavy scrutiny and debate in two specific 
areas affecting insurers: (1) brokers' commissions and (2) federal and state taxes. 
One of the ways in which some insurers have been cutting their administrative costs 
has been by cutting compensation to agents and brokers.  According to the Department of 
Health and Human Services (HHS) insurance brokers “are independent agents who receive 
commissions from an insurer for selling insurance products.”69 Brokers have many 
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important tasks such as (1) help employers design the “right” plan(s) for their employees; 
(2) explain the costs and benefits of the plan(s) to the insured; (3) resolve claims-related 
problems; and (4) refer customers to health insurance providers, thereby allowing the 
insurance companies to limit marketing-related expenses.
70
 Specifically, the brokers 
expressed concern regarding ACA counting their commissions counted as administrative 
expenses in the MLR calculation.  This has been the leading reason why insurers are 
already cutting commissions to improve medical loss ratios.”71 According to a survey by 
the National Association of Insurance and Financial Advisors (NAIFA) of “861 of its 
members who sell health insurance 70 percent of respondents who sell health insurance 
have seen a decrease in commissions since the MLR has gone into effect.”72  Additionally, 
state insurance agencies worried that they would be flooded with calls for help if the MLR 
pushed too many brokers out of business.
73
 This reduction of brokers comes at a time 
where our economy is at the weakest and millions of health care consumers need the most 
help. 
With regard to the Federal and State taxes at first glance, the Medical Loss Ratio 
may look like a good thing. Allowing insurers to deduct federal and state taxes which apply 
to their health insurance coverage from the insurer’s premium revenue is an attractive 
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feature of the MLR calculation provision.
74
 However, this provision may have the opposite 
effect on insurers. The significance of the MLR calculation depends on the detail of 
calculations. A smaller denominator makes the MLR requirement easier to meet.
75
 
Therefore, insurance companies naturally want to exclude as many taxes and fees as 
possible. However, the drafters of the ACA provided for provisions “that refer[s] only to 
Federal taxes and fees that relate specifically to revenue derived from the provision of 
health insurance coverage that were included in the ACA.”76 By allowing less opportunity 
to exclude taxes, this relatively narrow definition would make it more difficult for 
insurance companies to meet the ACA's minimum MLR requirements.
77
 The MLR as 
explained has the effect of keeping the carrier's profit down by requiring the carrier to 
spend more money in rebates than to the carrier's bottom line.  
III. Investing in Healthcare 
a. Quantitative Analysis 
Quantitative methods involves a review of the cash flow aspects of the transaction 
by employing statistical and mathematical tools that can be used to analyze information in 
order to estimate the expect gain or loss of an investment.
78
  The term quantitative analysis 
or research, while distinct, is often confused with qualitative analysis. Although qualitative 
and quantitative research are the two main schools of research and often used in tandem, 
quantitative analysis involves assembling statistical information that is absolute such as 
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numerical records, so that it can be examined in an impartial  manner.
79
  The central theory 
behind quantitative analysis is being able to isolated data easier so that they can be counted 
and evaluated statistically as well as remove outlying factors that may distract from the 
resolution of the inquiry.
80
 An analyst generally has a very clear idea what is being 
measured before they start measuring it and their study is set up with controls and a very 
clear blueprint. The result of quantitative research is a collection of numbers, which can  be 
subjected to statistical analysis, to come to the end results.  This result is what separate 
quantitative analysis from other forms which instead describe and analyze an occurrence 
using words.  
Formulating a financial speculation or hypothesis into a quantitative model allows 
analysts to apply statistical analysis to the problem and calculate the probability of certain 
outcomes such as, how likely a yield is to increase when a specific action is taken.
81
 For 
firms seeking to invest in a particular venture, quantitative methods are most commonly 
used to value different classes of securities (ie: stocks, bonds, debentures, notes),
82
 analyze 
criteria for guiding investment decisions, measure risk and asset return, and use statistical 
techniques for forecasting.
83
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b. Methods of Valuation 
When an event occurs that creates such sweeping reform inevitably there are 
winners and losers.  The job of analysts is to understand those consequences regardless of 
how we feel about the healthcare law.  Choosing an investment position in the health care 
market is not as simple as purchasing stocks based on news headlines; such strategy is 
generally a recipe for disaster.  With the healthcare industry soon becoming one of the 
largest segments of the United States economy with the massive expansion of insured 
individuals, it will be very critical for investors to maintain exposure to it so they can enjoy 
robust gains in addition to balanced portfolios.
84
  
In the view of analysts, valuation is based on fundamentals aimed to give an 
estimate of their intrinsic value of a company or its stock based on predictions of the future 
cash flows and profitability of the business.
85
 In financial markets, valuation is the method 
of calculating theoretical values of companies and their stocks. Knowing what an asset is 
worth and what determines that value is a pre-requisite for intelligent decision making 
when it comes to choosing an investments for a portfolio, in deciding on the appropriate 
price to pay or receive, and choosing to finance a business.
86
  
Analysts use a wide spectrum of models ranging from the simple to the 
sophisticated. These quantitative models often make very different assumptions that cannot 
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be assessed without analyzing the finances of a company.
87
 Each method it in its own way 
makes it easier to understand how an investment will fit into the big picture of your 
investment scheme. In general terms, there are two approaches to valuation. The first, 
Discounted Cash Flow valuation, relates the value of an asset to the present value of 
expected future cashflows on that asset.
88
 The second, relative valuation, estimates the 
value of an asset by looking at the pricing of comparable assets relative to a common 
variable like earnings, cashflows, book value or sales.
89
  
Discounted Cash Flow (DFC) is a valuation method used to estimate the 
attractiveness of an investment opportunity by analyzing future free cash flow projections 
and discounts the projections to arrive at a present value, which is used to evaluate the 
potential for investment.
90
 The principle of DCF is that a dollar received today is less 
valuable than a dollar received in the future.
91
 Therefore, the purpose of a DCF analysis is 
to anticipate returns in their present value (PV).
92
 This can be accomplished in one of two 
ways.  They are: Net Present Value (NPV) method and the Internal Rate of Return (IRR) 
method. 
93
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DISCOUNTED CASH FLOW 
  DCF = 
   
(   ) 
 + 
   
(   ) 
 + ….. + 
   
(   ) 
 
CF = Cash Flow 
r = Discount Rate (calculated by computing Weighted Average Cost of Capital (WACC)) 
 
Net present value (net cash flow) is the sum of the initial investment (a negative 
cash flow) plus the present values of future cash flows (which may be either negative or 
positive).
94
 If net present value is positive, the investment is profitable and a profit-seeking 
investor would pursue it. If the NPV were zero, the investor's assets would not change .  
The investment is neither profitable nor unprofitable, and a profit -seeking investor would 
be indifferent to it.
95
 If the NPV were negative, the financial value of the investor's assets 
would be decreased and the investment would not be financially attractive.
96
 An investment 
that is unprofitable, and a profit-seeking investor would avoid it.
97
 In summary, NPV or 
DCF determines the present dollar value of the future dollar returns and this amount is 
compared with the present value of the investment. If the present value of the return is 
greater than the present value of the investment, the investment is considered favorable.
98
 
An Internal Rate of Return (IRR) is a discount rate that makes all future cash 
receipts and expenditures equal to the initial cash investment.
99
  The use of internal rates of 
return permits different investments to be analyzed mathematically to determine which 
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ones have the greatest return after considering the time value of money.
100
 The IRR is that 
discount rate at which the PV of the anticipated total cash inflows is equal to the PV of the 
anticipated total cash outflows or the rate at which NPV is zero.
101
 IRR is determined 
through trial-and-error calculations using a mathematical formula (included with most 
spreadsheet programs) or a graph.
102
 IRR higher than the minimum acceptable rate of 
return, also known as the hurdle rate, indicates a desirable investment project. However, a 
project or investment with a lower projected IRR nonetheless may be preferable if that 
lower IRR can be earned on a larger principal amount.
103
 For example, an opportunity to 
earn 30% on a $100,000 investment brings greater absolute rewards than 40% on $1,000.
104
  
By evaluating the end result of either forms of DCF analysis, one can determine if 
an investment is a wise decision. A DCF outcome higher than the current cost of the 
investment results in a good investment opportunity.
105
 
The second method to valuation is by means of relative valuations. These  methods 
of valuations compare a firm's value to that of its competitors to determine the firm's 
financial worth.
106
 Relative valuation models are an alternative to absolute value models, 
which try to determine a company's intrinsic worth based on its estimated future free cash 
flows discounted to their present value.
107
 Investors use relative valuation models when 
determining whether a company should buy, sell or hold a particular stock or investment 
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option.
108
 These models are designed to take advantage of perceived mispricing among 
related financial assets and are often based on “the long-run tendency of market prices to 
revert to equilibrium relationships.”109 The simplest example of a relative value trade 
involves identifying a price divergence between two historically related stocks  and being 
the short position
110
 of the over-valued stock and the long position
111
 on the historically 
under-valued stock.
112
 Valuing securities entails expending efforts to uncover information, 
assessing its relevance, and determining the proper quantitative price change that properly 
reflects the information.
113
 
Net Margin           
        
 
EBITDA Margin       
       
 
Return on Equity           
            
 
Consolidated 
Medical Cost 
Ratio
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Book Value      
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The main advantage of relative valuation is that it reflects market volatility, 
enabling investors to realize at any given moment if it is to their best interest to sell a stock 
or to invest building momentum.
115
 In addition, relative valuation provides portfolio 
managers with a variety of securities that are overvalued or undervalued, thus enabling 
them to build more diversified portfolios.
116
  
 
IV. Wall Street’s Response 
This paper takes the position that although regulation is needed in order to prevent 
fraud, ensure fair competition and to provide affordable health care for all,  instituting 
specific regulatory action such as the medical device tax creates more complications and 
potential harm than potential gains. 
Robert Field
117
 addresses the similar issue pertaining to governments reoccurring 
involvement in the private pharmaceutical industry.
118
  The pharmaceutical industry has 
grown to be and continuously remains a successful investment because of the ability to 
constantly enter the market to replenish the supply.
119
  Advocating for government’s 
involvement, Field stressed the continually participation was an indispensable catalyst for 
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market growth.
120
  Without government assistance, the private sector would not have 
realized large and robust gains.
121
  However, there are some clear distinctions that separate 
Field’s analysis of the pharmaceutical industry with that of the medical device industry.  
Most notably, the government encouraged growth of pharmaceutical discoveries by 
offering tax credits to companies conducting research.
122
 These tax credits became very 
valuable especially for private firms who were reluctant to invest in initial product 
development. This cannot be said of the 2.3% medical devise tax.  Typically, excise taxes 
are used to discourage consumption of potentially dangerous substances, such as tobacco 
and alcohol, which might be abused or over consumed if not for the absence of taxation.
123
 
An industry survey discovered 70 percent of device makers thought this tax would have a 
negative impact and would result in oppressive compliance measures.
124
 When analyzing 
financial investment options, investors seek to avail themselves to sufficient returns or 
investors will seed their capital elsewhere despite record low interest rates. To see how the 
device tax stymies private investment, Forbes analyzed Hill-Rom (“HRC”), a hospital bed 
producer.
125
 Over the past year HRC generated $1,633 million in revenue and earned 
$145.1 million of net income.
126
 Hill-Rom’s return on equity (“ROE”) totaled 18.6 
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percent.
127
 At 2.3 percent of gross revenue, the device tax knocks net income down to $108 
million slashing ROE to 13.7 percent.
128
  
Another theory Field’s puts forth is the need for governmental presence as a 
provider of public trust and confidence in the industry.
129
 Political debates over economic 
policy commonly pit the virtues of the free market against those of government oversight. 
When health care policy is discussed it is normally done so just in the context of the 
vacuum that is the health care industry.  Policy makers often do not appreciate how the 
policies they enact affect the industries around them especially the markets on Wall Street.  
Although the medical device industry is known for commitment to shareholder returns with 
growth potential from emerging markets and new products,
130
 quantitative analytics by 
performed Wall Street analysts may prove that these new regulations and taxes imposed no 
longer make healthcare sub-sectors attractive for investors.  In a study co-sponsored by the 
National Venture Capital Association (“NVCA”) and the Medical Innovation & 
Competitiveness Coalition, 42 percent of venture capital firms planned to make fewer 
medical device investments over the next three years and 61 percent of venture capitalist 
survey respondents identified regulatory concerns as the most significant factor affecting 
their investment decisions.
131
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With the January 2013 passage of  the  medical device tax, venture capitalists are looking 
at prospects for their return-on-investment and now actively factoring in the economic effects of 
the excise tax on their prospective clients.  The result is that this excise tax is making it difficult 
for smaller innovative medical device firms to acquire venture capital necessary to survive and 
prosper a determining factor of why the pharmaceutical industry has thrived with government 
assistance.
132
   
This unintended effect seems to be counter intuitive to the overall goals of the Affordable 
Care Act, which is to cut costs and make healthcare available to all.
133
  A prime example is the 
creations of ACOs which are intended to lower the cost of healthcare by creating incentives to 
improve the quality of care.
134
  However, a penalizing tax on medical devices has a contrary 
effect to the cost of healthcare.
135
  Predictive healthcare, such as a microchip implant that sends 
blood chemical results via Bluetooth to predict whether an individual is likely to have a heart 
attacks, could be obsolete without such investments in medical device R&D and in the end cost 
individual and insurers more money.
136
   The National Bureau of Economics recently found that 
cardiovascular disease costs the United States $110 billion annually.
137
 In addition, for an 
individual who has had a heart attack, the average cost to traditional health insurers for the first 
90 days following a heart attack is $38,501.
138
  Furthermore, Medicare spends over $14,000 per 
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patient on hospital bills in the year after a heart attack, plus additional amounts for physicians 
and outpatient care. 
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Nevertheless, the greatest source of reassurance for investors is the quality of the 
investment themselves.   For the medical device tax to have the same effect as government 
intervention in the pharmaceutical context, entrepreneurship and innovation need to be the 
catalyst for growth.   
V. Conclusion  
The health care industry is a sector that strives on free market economics dependent 
upon private investments and firm competition. The economic implications stemming from 
PPACA may significantly hinder the way our health care industry functions. The 27 taxes 
found within in ACA in order to raise revenues for universal health care may prove 
debilitating to medical device companies, American patients, and the U.S. economy.  As 
the market responses to the changes, it is quite likely that many small innovative medical 
device companies will not receive the venture capital funding necessary to fund their 
devices and thus they will not be able to provide their life sustaining technologies to 
patients.  The more cognizant policy makers are of capital market trends and conscious of 
the quantitative consequence of their decisions, the health care industry may be able to 
limit instability within the sector and move toward the overall goals in the Affordable Care 
Act. 
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